» Articles » PMID: 33928470

Clinical Features of Migraine with Onset Prior to or During Start of Combined Hormonal Contraception: a Prospective Cohort Study

Overview
Publisher Springer
Specialty Neurology
Date 2021 Apr 30
PMID 33928470
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Many studies have described the features of menstrually related migraines but there is a lack of knowledge regarding the features of migraine in combined hormonal contraceptive users (CHC). Hormone-withdrawal migraines in the pill-free period could differ from those in the natural cycle. Gynaecologic comorbidities, like dysmenorrhea and endometriosis, but also depression or a family history might modify the course of migraine. A better understanding of migraine features linked to special hormonal situations could improve treatment. For this prospective cohort study, we conducted telephone interviews with women using a CHC and reporting withdrawal migraine to collect information on migraine frequency, intensity, triggers, symptoms, pain medication, gynaecologic history and comorbidities (n = 48). A subset of women agreed to also document their migraines in prospective diaries. The mean number of migraine days per cycle was 4.2 (± 2.7). Around 50% of these migraines occurred during the hormone-free interval. Migraine frequency was significantly higher in women who suffered from migraine before CHC start (5.0 ± 3.1) (n = 22) in comparison to those with migraine onset after CHC start (3.5 ± 2.1) (n = 26). Menstrually related attacks were described as more painful (57.5%), especially in women with migraine onset before CHC use (72%) (p < 0.02). Comorbidities were rare, except dysmenorrhea. The majority of migraine attacks in CHC users occur during the hormone-free interval. Similar as in the natural cycle, hormone-withdrawal migraines in CHC users are very intense and the response to acute medication is less good, especially in those women, who developed migraine before CHC use.

Citing Articles

Investigating migraine phenotype and dynamics in women with endometriosis: an observational pilot study.

Merki-Feld G, Dietrich H, Imesch P, Gantenbein A, Sandor P, Schankin C Acta Neurol Belg. 2024; 124(4):1263-1271.

PMID: 38878131 PMC: 11266208. DOI: 10.1007/s13760-024-02484-2.

References
1.
. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

2.
Ferrari A, Leone S, Vergoni A, Bertolini A, Sances G, Coccia C . Similarities and differences between chronic migraine and episodic migraine. Headache. 2007; 47(1):65-72. DOI: 10.1111/j.1526-4610.2006.00629.x. View

3.
Vetvik K, MacGregor E, Lundqvist C, Russell M . Symptoms of premenstrual syndrome in female migraineurs with and without menstrual migraine. J Headache Pain. 2018; 19(1):97. PMC: 6755584. DOI: 10.1186/s10194-018-0931-6. View

4.
Peris F, Donoghue S, Torres F, Mian A, Wober C . Towards improved migraine management: Determining potential trigger factors in individual patients. Cephalalgia. 2016; 37(5):452-463. DOI: 10.1177/0333102416649761. View

5.
Loder E, Buse D, Golub J . Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol. 2005; 193(3 Pt 1):636-49. DOI: 10.1016/j.ajog.2004.12.089. View